As the largest resource of information specific to women's brain health, we are sure you will find what you are looking for, and promise that you will discover new information.
Published on: May 2, 2012
by The Press Association
A highly-toxic protein described as the “real bad guy” behind Alzheimer’s disease has been identified by scientists.
The molecule recruits other less harmful proteins and makes them deadly to brain cells, according to research published in the online edition of the journal Nature. Knowing how it forms and behaves is expected to lead to more effective Alzheimer’s treatments. One experimental drug to emerge from the research has already completed early phase I clinical trials.
The protein is a special type of beta-amyloid, which was already known to play a key role in Alzheimer’s. Beta-amyloid clumps together in the brains of Alzheimer’s patients, forming deposits that result in the destruction of nerve cells.
“This form of beta-amyloid, called pyroglutamylated (or pyroglu) beta-amyloid, is a real bad guy in Alzheimer’s disease,” said lead scientist Professor George Bloom, from the University of Virginia in the United States.
“We’ve confirmed that it converts more abundant beta-amyloids into a form that is up to 100 times more toxic, making this a very dangerous killer of brain cells and an attractive target for drug therapy.”
He compared the way the protein spread destruction in the brain to the transmission of prion diseases, such as Creutzfeldt Jakob Disease (CJD). Prion diseases are caused by rogue misshapen proteins that toxify other proteins they come into contact with in a chain reaction.
“You might think of this pyroglu beta-amyloid as a seed that can further contaminate something that’s already bad into something much worse – it’s the trigger,” said Prof Bloom.
Co-author Dr Hans-Ulrich Demuth, chief scientific officer at the German biotech company Probiodrug, said: “This publication further adds significant evidence to our hypothesis about the critical role pyroglu beta-amyloid plays in the initiation of Alzheimer’s disease.”
Probiodrug, based in Halle, has completed phase I safety trials of a drug that suppresses an enzyme involved in the formation of pyroglu beta-amyloid.
Yale researchers have tested a new method for directly measuring synaptic loss in individuals with Alzheimer’s disease. The method, which uses PET imaging technology to scan for a specific protein in the brain linked to synapses, has...
Sometimes, the hardest part of living with a mental illness isn’t the symptoms, or the management — it’s dealing with stigma from other people. And unfortunately, many people who live with mental illness face stigma...
The root cause of behavioural outbursts in someone with Alzheimer’s disease is mostly due to the decline in the person’s language and communication skills. Outbursts also can be caused by an unmet need or needs. The affected...
The material presented through the Think Tank feature on this website is in no way intended to replace professional medical care or attention by a qualified practitioner. WBHI strongly advises all questioners and viewers using this feature with health problems to consult a qualified physician, especially before starting any treatment. The materials provided on this website cannot and should not be used as a basis for diagnosis or choice of treatment. The materials are not exhaustive and cannot always respect all the most recent research in all areas of medicine.